Yu Qin, Tan Rui-Zhi, Gan Quan, Zhong Xia, Wang You-Qiang, Zhou Jing, Wang Li
School of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, Sichuan, China.
Research Center of Combine Traditional Chinese and Western Medicine, Affiliated Traditional Medicine Hospital, Southwest Medical University, Luzhou, 646000, Sichuan, China.
Mol Biotechnol. 2017 Oct;59(9-10):365-373. doi: 10.1007/s12033-017-0025-8.
CRISPR/Cas technology has been widely used in generating conventional and conditional gene knockout animals through germline mutation. A recent study has demonstrated that CRISPR/Cas system also worked on nongermline mutation in mice liver via hydrodynamic injection of vector plasmid to blood circulation. However, whether this is also applied to rat and what is the optimal concentration of vector plasmid still need to be studied. Here, we attempted to use pX330-Pten plasmid to knock down the expression of Pten in rat liver for generation of nonalcoholic fatty liver disease (NAFLD) rat model. A range of pX330-Pten dosages (75, 150 and 300 μg/100 g) in 10 ml of saline water was injected into the blood circulation of SD rats within 30 s by tail vein injection. The data showed that, 9 weeks after injection, no differences of TC, AST and ALT were found between control and the treatment groups (low-dose, mid-dose, high-dose and fat-diet groups). However, the high-dose group revealed severe lipid deposition and significant knockdown of Pten, which was validated by western blot and real-time PCR. Notably, lipid deposition and Pten knockdown were detected in the liver of animals from the high-dose group as early as 6 weeks after injection. Taken together, our findings demonstrated that hydrodynamic injection of pX330-Pten plasmid at the dosage of 300 μg/100 g can knock down the expression of Pten in rat liver efficiently, resulting in lipid deposition as well as NAFLD. Taken together, this study presents a novel and efficient method to edit genome in rat liver.
CRISPR/Cas技术已广泛应用于通过种系突变来生成传统的和条件性基因敲除动物。最近一项研究表明,通过向血液循环中流体动力学注射载体质粒,CRISPR/Cas系统在小鼠肝脏的非种系突变中也能发挥作用。然而,这是否也适用于大鼠以及载体质粒的最佳浓度仍有待研究。在此,我们尝试使用pX330-Pten质粒来敲低大鼠肝脏中Pten的表达,以生成非酒精性脂肪性肝病(NAFLD)大鼠模型。将一系列剂量(75、150和300 μg/100 g)的pX330-Pten溶于10 ml生理盐水中,通过尾静脉注射在30秒内注入SD大鼠的血液循环。数据显示,注射后9周,对照组与治疗组(低剂量、中剂量、高剂量和高脂饮食组)之间的总胆固醇(TC)、谷草转氨酶(AST)和谷丙转氨酶(ALT)没有差异。然而,高剂量组显示出严重的脂质沉积以及Pten的显著敲低,这通过蛋白质免疫印迹法(western blot)和实时定量聚合酶链反应(real-time PCR)得到验证。值得注意的是,早在注射后6周就在高剂量组动物的肝脏中检测到了脂质沉积和Pten敲低。综上所述,我们的研究结果表明,以300 μg/100 g的剂量流体动力学注射pX330-Pten质粒可以有效敲低大鼠肝脏中Pten的表达,导致脂质沉积以及NAFLD。综上所述,本研究提出了一种在大鼠肝脏中编辑基因组的新颖且有效的方法。